Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions

Melody Hermel; Stacy Tsai; Luis Dlouhy; Anupama B K; Jamal S. Rana; Sourbha S. Dani; Salim S. Virani

doi:10.1007/s11883-022-01042-6

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions

Melody Hermel, Stacy Tsai, Luis Dlouhy, Anupama B K, Jamal S. Rana, Sourbha S. Dani, Salim S. Virani

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

Abstract

Purpose of Review: Focused review highlighting select studies presented at the 2022 American College of Cardiology (ACC) Scientific Sessions. Recent Findings: Included studies assessed the impact of a low-sodium diet on heart failure outcomes (SODIUM-HF); outcomes of pregnant patients with chronic hypertension treated with antihypertensive therapies (CHAP); cardiovascular outcomes in patients with type 2 diabetes and renal impairment treated with sotagliflozin (SCORED); a safety and efficacy study investigating SLN360, a short interfering RNA targeting lipoprotein(a) (APOLLO); a supermarket and web-based intervention targeting nutrition for cardiovascular risk reduction (SuperWIN); a superiority trial comparing myocardial injury following very mild perioperative hypothermia versus aggressive warming after non-cardiac surgery (PROTECT); and 3-year efficacy outcomes of renal denervation on blood pressure reduction from the SPYRAL HTN-ON MED pilot study. Summary: Research presented at the 2022 ACC Scientific Sessions underscores the new potential and meaningful impact of cardiovascular disease prevention and management interventions.

Original language	English (UK)
Pages (from-to)	671-680
Number of pages	10
Journal	Current Atherosclerosis Reports
Volume	24
Issue number	8
DOIs	https://doi.org/10.1007/s11883-022-01042-6
Publication status	Published - Aug 2022
Externally published	Yes

Keywords

Cardiovascular prevention
DASH diet
Heart failure
Hypertension
Lipoprotein(a)
Sotagliflozin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11883-022-01042-6

Cite this

@article{fa853c8c04a94c5495448721b21050ea,

title = "Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions",

abstract = "Purpose of Review: Focused review highlighting select studies presented at the 2022 American College of Cardiology (ACC) Scientific Sessions. Recent Findings: Included studies assessed the impact of a low-sodium diet on heart failure outcomes (SODIUM-HF); outcomes of pregnant patients with chronic hypertension treated with antihypertensive therapies (CHAP); cardiovascular outcomes in patients with type 2 diabetes and renal impairment treated with sotagliflozin (SCORED); a safety and efficacy study investigating SLN360, a short interfering RNA targeting lipoprotein(a) (APOLLO); a supermarket and web-based intervention targeting nutrition for cardiovascular risk reduction (SuperWIN); a superiority trial comparing myocardial injury following very mild perioperative hypothermia versus aggressive warming after non-cardiac surgery (PROTECT); and 3-year efficacy outcomes of renal denervation on blood pressure reduction from the SPYRAL HTN-ON MED pilot study. Summary: Research presented at the 2022 ACC Scientific Sessions underscores the new potential and meaningful impact of cardiovascular disease prevention and management interventions.",

keywords = "Cardiovascular prevention, DASH diet, Heart failure, Hypertension, Lipoprotein(a), Sotagliflozin",

author = "Melody Hermel and Stacy Tsai and Luis Dlouhy and \{B K\}, Anupama and Rana, \{Jamal S.\} and Dani, \{Sourbha S.\} and Virani, \{Salim S.\}",

note = "Publisher Copyright: {\textcopyright} 2022, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.",

year = "2022",

month = aug,

doi = "10.1007/s11883-022-01042-6",

language = "English (UK)",

volume = "24",

pages = "671--680",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Springer",

number = "8",

}

TY - JOUR

T1 - Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions

AU - Hermel, Melody

AU - Tsai, Stacy

AU - Dlouhy, Luis

AU - B K, Anupama

AU - Rana, Jamal S.

AU - Dani, Sourbha S.

AU - Virani, Salim S.

PY - 2022/8

Y1 - 2022/8

N2 - Purpose of Review: Focused review highlighting select studies presented at the 2022 American College of Cardiology (ACC) Scientific Sessions. Recent Findings: Included studies assessed the impact of a low-sodium diet on heart failure outcomes (SODIUM-HF); outcomes of pregnant patients with chronic hypertension treated with antihypertensive therapies (CHAP); cardiovascular outcomes in patients with type 2 diabetes and renal impairment treated with sotagliflozin (SCORED); a safety and efficacy study investigating SLN360, a short interfering RNA targeting lipoprotein(a) (APOLLO); a supermarket and web-based intervention targeting nutrition for cardiovascular risk reduction (SuperWIN); a superiority trial comparing myocardial injury following very mild perioperative hypothermia versus aggressive warming after non-cardiac surgery (PROTECT); and 3-year efficacy outcomes of renal denervation on blood pressure reduction from the SPYRAL HTN-ON MED pilot study. Summary: Research presented at the 2022 ACC Scientific Sessions underscores the new potential and meaningful impact of cardiovascular disease prevention and management interventions.

AB - Purpose of Review: Focused review highlighting select studies presented at the 2022 American College of Cardiology (ACC) Scientific Sessions. Recent Findings: Included studies assessed the impact of a low-sodium diet on heart failure outcomes (SODIUM-HF); outcomes of pregnant patients with chronic hypertension treated with antihypertensive therapies (CHAP); cardiovascular outcomes in patients with type 2 diabetes and renal impairment treated with sotagliflozin (SCORED); a safety and efficacy study investigating SLN360, a short interfering RNA targeting lipoprotein(a) (APOLLO); a supermarket and web-based intervention targeting nutrition for cardiovascular risk reduction (SuperWIN); a superiority trial comparing myocardial injury following very mild perioperative hypothermia versus aggressive warming after non-cardiac surgery (PROTECT); and 3-year efficacy outcomes of renal denervation on blood pressure reduction from the SPYRAL HTN-ON MED pilot study. Summary: Research presented at the 2022 ACC Scientific Sessions underscores the new potential and meaningful impact of cardiovascular disease prevention and management interventions.

KW - Cardiovascular prevention

KW - DASH diet

KW - Heart failure

KW - Hypertension

KW - Lipoprotein(a)

KW - Sotagliflozin

UR - https://www.scopus.com/pages/publications/85131075672

U2 - 10.1007/s11883-022-01042-6

DO - 10.1007/s11883-022-01042-6

M3 - Review article

C2 - 35633463

AN - SCOPUS:85131075672

SN - 1523-3804

VL - 24

SP - 671

EP - 680

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 8

ER -

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this